Cargando…

An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition

Glioblastoma (GBM) is the most common primary malignant tumor in the brain, accounting for 51.4% of all primary brain tumors. GBM has a highly immunosuppressive tumor microenvironment (TME) and, as such, responses to immunotherapeutic strategies are poor. Vaccinia virus (VV) is an oncolytic virus th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yijie, Zhang, Zhe, Zhang, Chenglin, Zhang, Na, Wang, Pengju, Chu, Yongchao, Chard Dunmall, Louisa S., Lemoine, Nicholas R., Wang, Yaohe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233193/ https://www.ncbi.nlm.nih.gov/pubmed/35795092 http://dx.doi.org/10.1016/j.omto.2022.05.008

Ejemplares similares

A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma
por: Zhang, Zifang, et al.
Publicado: (2020)

A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer
por: Wang, Na, et al.
Publicado: (2020)

Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment
por: Wang, Lihong, et al.
Publicado: (2022)

A new oncolytic Vaccinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery
por: Ahmed, Jahangir, et al.
Publicado: (2020)

Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus
por: Ferguson, Mark S., et al.
Publicado: (2020)

Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy
por: Jia, Yangyang, et al.
Publicado: (2023)

A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer
por: Marelli, Giulia, et al.
Publicado: (2021)

Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene
por: Cao, Dujuan, et al.
Publicado: (2022)

Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL
por: Zhou, Wenping, et al.
Publicado: (2023)

Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy
por: Baleeiro, Renato B., et al.
Publicado: (2022)

Treatment and Prevention of Lung Cancer Using a Virus-Infected Reprogrammed Somatic Cell-Derived Tumor Cell Vaccination (VIReST) Regime
por: Zhang, Zhe, et al.
Publicado: (2020)

Patient-derived xenograft: a developing tool for screening biomarkers and potential therapeutic targets for human esophageal cancers
por: Lan, Tianfeng, et al.
Publicado: (2021)

Natural products targeting glycolysis in cancer
por: Zhao, Yuanyuan, et al.
Publicado: (2022)

A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9
por: Yuan, Ming, et al.
Publicado: (2015)

Characterization of the Intra-tumoral B Cell Immunoglobulin Repertoire Is of Prognostic Value for Esophageal Squamous Cell Carcinoma
por: Wang, Zhizhong, et al.
Publicado: (2022)

Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus
por: Kirn, David H, et al.
Publicado: (2007)

Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles
por: Ferguson, Mark S., et al.
Publicado: (2012)

Ferroptosis-Related Genes Are Potential Therapeutic Targets and the Model of These Genes Influences Overall Survival of NSCLC Patients
por: Zhang, Na, et al.
Publicado: (2022)

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles
por: Wong, Han Hsi, et al.
Publicado: (2010)

Update on oncolytic viral therapy – targeting angiogenesis
por: Tysome, James R, et al.
Publicado: (2013)

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Chen, Tianyue, et al.
Publicado: (2021)

Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours
por: Hiley, Crispin T, et al.
Publicado: (2009)

Deoxythymidylate Kinase as a Promising Marker for Predicting Prognosis and Immune Cell Infiltration of Pan-cancer
por: Lan, Tianfeng, et al.
Publicado: (2022)

Oncolytic Viruses—Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer
por: Howells, Anwen, et al.
Publicado: (2017)

CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses
por: Yuan, Ming, et al.
Publicado: (2016)

Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer
por: Brito Baleeiro, Renato, et al.
Publicado: (2023)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer
por: Marelli, Giulia, et al.
Publicado: (2018)

MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy
por: Baleeiro, Renato B., et al.
Publicado: (2022)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
por: Wang, Pengju, et al.
Publicado: (2017)

Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
por: Wang, Pengju, et al.
Publicado: (2018)

Theranostic Potential of Oncolytic Vaccinia Virus
por: Rojas, Juan J, et al.
Publicado: (2012)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Oncolytic properties of non-vaccinia poxviruses
por: Ricordel, Marine, et al.
Publicado: (2018)

Correction: IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Publicado: (2021)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
por: Chen, Nanhai, et al.
Publicado: (2013)

Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma
por: Deng, Lili, et al.
Publicado: (2022)

Antitumor activity of recombinant oncolytic vaccinia virus with human IL2
por: Liu, Liqiong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_no109re3p05e533s2g6p915iln